Also known as: Azilect; Rasagiline Mesylate; TVP-1012
Rasagiline is a pharmaceutical-grade active ingredient classified as an irreversible MAO-B Inhibitor Anti-Parkinsonian agent. Mediocon Inc supplies high-purity Rasagiline API conforming to IP / BP / EP / USP specifications, manufactured in our GMP-certified facility in Aurangabad, Maharashtra, India.
Rasagiline is an irreversible and selective inhibitor of monoamine oxidase type B (MAO-B), used in the treatment of Parkinson's disease both as monotherapy and as adjunct to levodopa. By inhibiting dopamine breakdown, rasagiline improves motor symptoms and extends levodopa efficacy, delaying disease progression.
Key Features
Applications
Why Choose Mediocon
| Parameter | Specification |
|---|---|
| Assay | NLT 98.0% |
| Loss on Drying | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Residue on Ignition | NMT 0.1% |
| Microbial Limits | Complies with pharmacopoeia |
| Identification | IR, HPLC Compliant |
| Packing | 25 kg HDPE drums / as per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Rasagiline (CAS 136236-51-6) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Rasagiline is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance